We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Delegated Act Spells Out Situations Requiring Postmarketing Studies
Delegated Act Spells Out Situations Requiring Postmarketing Studies
Sponsors that use surrogate endpoints, such as biomarkers, in confirmatory cancer trials may need to provide postmarketing data to the European Medicines Agency verifying that the information used to gain marketing authorization remains valid in practice.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor